# Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

> **NCT01903122** · EARLY_PHASE1 · COMPLETED · sponsor: **Roxane Laboratories** · enrollment: 26 (actual)

## Conditions studied

- Dry Mouth

## Interventions

- **DRUG:** Cevimeline

## Key facts

- **NCT ID:** NCT01903122
- **Lead sponsor:** Roxane Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903122, "Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01903122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*